Breaking News Instant updates and real-time market news.

SIXGF

Sixt

$142.00 /

+ (+0.00%)

12:32
05/17/21
05/17
12:32
05/17/21
12:32

Sixt price target raised to EUR 140 from EUR 135 at Deutsche Bank

Deutsche Bank analyst Michael Kuhn raised the firm's price target on Sixt to EUR 140 from EUR 135 and keeps a Buy rating on the shares.

SIXGF Sixt
$142.00 /

+ (+0.00%)

03/24/21 Deutsche Bank
Sixt initiated with a Buy at Deutsche Bank
03/04/21 Jefferies
Sixt downgraded to Hold from Buy at Jefferies
03/03/21 Commerzbank
Sixt upgraded to Buy from Hold at Commerzbank
03/03/21 DZ Bank
Sixt upgraded to Buy from Hold at DZ Bank

TODAY'S FREE FLY STORIES

Periodicals
DocuSign a smarter meme trade, Barron's says » 11:12
06/12/21
06/12
11:12
06/12/21
11:12
DOCU

DocuSign

$253.05 /

+9.9 (+4.07%)

, GME

GameStop

$233.03 /

+13 (+5.91%)

, AMC

AMC Entertainment

$49.32 /

+6.435 (+15.01%)

DocuSign (DOCU), whose…

DocuSign (DOCU), whose electronic signature technology is replacing the old way of signing documents with pens, has an anemic price compared with popular meme stocks like GameStop (GME) or AMC Entertainment (AMC), Steven Sears writes in this week's edition of Barron's. The disconnect between the stock of a company at the leading edge of technology and companies with arguably archaic offerings is worth addressing, the author notes. Reference Link

ShowHide Related Items >><<
GME GameStop
$233.03 /

+13 (+5.91%)

DOCU DocuSign
$253.05 /

+9.9 (+4.07%)

AMC AMC Entertainment
$49.32 /

+6.435 (+15.01%)

DOCU DocuSign
$253.05 /

+9.9 (+4.07%)

06/10/21 RBC Capital
DocuSign assumed with an Outperform at RBC Capital
06/04/21 Wedbush
DocuSign price target lowered to $260 from $300 at Wedbush
06/04/21 Morgan Stanley
DocuSign price target raised to $295 from $290 at Morgan Stanley
06/04/21 Oppenheimer
DocuSign price target lowered to $260 from $300 at Oppenheimer
GME GameStop
$233.03 /

+13 (+5.91%)

06/10/21 Wedbush
GameStop price target raised to $50 from $39 at Wedbush
06/04/21 BofA
BofA moves to No Rating on Bed Bath & Beyond amid 'meme mania'
06/04/21 BofA
GameStop coverage terminated at BofA
04/12/21
Fly Intel: Top five analyst downgrades
AMC AMC Entertainment
$49.32 /

+6.435 (+15.01%)

06/08/21 MKM Partners
AMC Entertainment shareholders best served by lower debt, says MKM Partners
06/07/21 B. Riley
Box office trends improving into summer, says B. Riley
06/04/21 Wedbush
AMC Entertainment price target raised to $7.50 from $6.50 at Wedbush
GME GameStop
$233.03 /

+13 (+5.91%)

DOCU DocuSign
$253.05 /

+9.9 (+4.07%)

AMC AMC Entertainment
$49.32 /

+6.435 (+15.01%)

GME GameStop
$233.03 /

+13 (+5.91%)

DOCU DocuSign
$253.05 /

+9.9 (+4.07%)

AMC AMC Entertainment
$49.32 /

+6.435 (+15.01%)

GME GameStop
$233.03 /

+13 (+5.91%)

DOCU DocuSign
$253.05 /

+9.9 (+4.07%)

AMC AMC Entertainment
$49.32 /

+6.435 (+15.01%)

GME GameStop
$233.03 /

+13 (+5.91%)

DOCU DocuSign
$253.05 /

+9.9 (+4.07%)

AMC AMC Entertainment
$49.32 /

+6.435 (+15.01%)

Periodicals
UPS shares a buy now, Barron's says » 11:08
06/12/21
06/12
11:08
06/12/21
11:08
UPS

UPS

$203.24 /

+0.065 (+0.03%)

UPS stock is still a buy,…

UPS stock is still a buy, even after this past week's disappointing investor event, Al Root writes in this week's edition of Barron's. The world is a very different place that it was a few years ago, and that should help the company's business-and its price/earnings multiple, the author notes. Reference Link

ShowHide Related Items >><<
UPS UPS
$203.24 /

+0.065 (+0.03%)

UPS UPS
$203.24 /

+0.065 (+0.03%)

06/10/21
Fly Intel: Top five analyst upgrades
06/10/21 BMO Capital
UPS price target raised to $200 from $195 at BMO Capital
06/10/21 Oppenheimer
UPS price target raised to $222 from $210 at Oppenheimer
06/10/21 Stephens
UPS event 'failed to live up to raised investor expectations,' says Stephens
UPS UPS
$203.24 /

+0.065 (+0.03%)

UPS UPS
$203.24 /

+0.065 (+0.03%)

UPS UPS
$203.24 /

+0.065 (+0.03%)

UPS UPS
$203.24 /

+0.065 (+0.03%)

Periodicals
TSMC caught up in rare correction, investors should avoid buying, Barron's says » 11:05
06/12/21
06/12
11:05
06/12/21
11:05
TSM

TSMC

$118.28 /

+0.0599 (+0.05%)

TSMC shares are now…

TSMC shares are now caught up in a rare correction, with the stock down 15% since mid-February, but investors should avoid the temptation to buy on the dip, at least for now, Reshma Kapadia writes in this week's edition of Barron's. A confluence of factors could make the next couple of quarters bumpy enough to give long-term investors a chance to scoop up shares of the tech juggernaut at an even cheaper price, the author adds. However, the long-term opportunity hasn't changed, the publication notes. Reference Link

ShowHide Related Items >><<
TSM TSMC
$118.28 /

+0.0599 (+0.05%)

TSM TSMC
$118.28 /

+0.0599 (+0.05%)

05/18/21 New Street
New Street would be buyers of Tesla amid current selloff
04/21/21 Needham
Advanced Energy price target raised to $135 from $128 at Needham
04/21/21 Needham
Axcelis price target raised to $47 from $44 at Needham
04/21/21 Needham
Ichor Holdings price target raised to $64 from $46 at Needham
TSM TSMC
$118.28 /

+0.0599 (+0.05%)

TSM TSMC
$118.28 /

+0.0599 (+0.05%)

TSM TSMC
$118.28 /

+0.0599 (+0.05%)

TSM TSMC
$118.28 /

+0.0599 (+0.05%)

Periodicals
Lilly, Roche may benefit from approval of Biogen Alzheimer's drug, Barron's says » 10:49
06/12/21
06/12
10:49
06/12/21
10:49
LLY

Eli Lilly

$224.12 /

-9.42 (-4.03%)

, RHHBY

Roche

$47.56 /

-0.22 (-0.46%)

, BIIB

Biogen

$396.46 /

-18.29 (-4.41%)

When the U.S. Food and…

When the U.S. Food and Drug Administration approved Aduhelm, Biogen's (BIIB) Alzheimer's disease therapy, this past Monday, it did so on the basis of the drug's ability to reduce the level of junk proteins in patients' brains, Josh Nathan-Kazis writes in this week's edition of Barron's. The agency believes that clearing those proteins, called amyloid plaques, reduces cognitive decline, he adds, noting that the move now opens the possibility of approvals for other drugs that, like Aduhelm, can clear amyloid plaque, but haven't been proven definitively to slow cognitive decline. Eli Lilly's (LLY) donanemab is one. Gantenerumab, from Roche Holding (RHHBY), is another. Biogen and its partner, Eisai (ESALY), have a third, known as BAN2401. Reference Link

ShowHide Related Items >><<
RHHBY Roche
$47.56 /

-0.22 (-0.46%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

06/08/21 Baird
Baird upgrades Biogen to Neutral after 'fatal blow' to bear thesis
06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
05/27/21 H.C. Wainwright
H.C. Wainwright bullish on Dicerna as new RNAi candidate enters clinic
05/24/21 H.C. Wainwright
Aurinia reported positive data as competitors 'stumble,' says H.C. Wainwright
RHHBY Roche
$47.56 /

-0.22 (-0.46%)

06/10/21 Morgan Stanley
Roche price target raised to CHF 370 from CHF 345 at Morgan Stanley
06/02/21 Societe Generale
Roche downgraded to Hold from Buy at Societe Generale
05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
BIIB Biogen
$396.46 /

-18.29 (-4.41%)

06/11/21
Fly Intel: Top five analyst upgrades
06/11/21 Bernstein
Biogen upgraded to Outperform from Market Perform at Bernstein
06/11/21 RBC Capital
Prothena price target raised to $50 from $28 at RBC Capital
06/11/21 Bernstein
Biogen upgraded to Outperform from Market Perform at Bernstein
RHHBY Roche
$47.56 /

-0.22 (-0.46%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

RHHBY Roche
$47.56 /

-0.22 (-0.46%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

RHHBY Roche
$47.56 /

-0.22 (-0.46%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

On The Fly
Opening Day: Monday.com, Marqeta jump in market debuts » 08:04
06/12/21
06/12
08:04
06/12/21
08:04
ATY

AcuityAds

$11.58 /

+1.01 (+9.56%)

, MQ

Marqeta

$31.50 /

+1.85 (+6.24%)

, JANX

Janux Therapeutics

$25.00 /

-9.17 (-26.84%)

, TASK

TaskUs

$31.34 /

+3.685 (+13.32%)

, BZ

Kanzhun

$37.67 /

+4.32 (+12.95%)

, MNDY

Monday.com

$194.99 /

+18.88 (+10.72%)

, LFST

LifeStance

$24.00 /

+2.27 (+10.45%)

, ZETA

Zeta Global

$8.26 /

-0.635 (-7.14%)

, DIBS

1stDibs

$24.61 /

-3.53 (-12.54%)

, DASH

DoorDash

$154.18 /

+9.475 (+6.55%)

, ZME

Zhangmen Education

$13.43 /

-0.56 (-4.00%)

, PCOR

Procore

$83.98 /

-2.47 (-2.86%)

, OTLY

Oatly Group

$28.71 /

+2.01 (+7.53%)

, DIDI

DiDi

/

+

, QNIU

Qiniu

/

+

, SVFD

Save Foods

$8.80 /

+0.05 (+0.57%)

, RGCB

Regencell Bioscience

/

+

, ELEV

Elevation Oncology

/

+

, CMSL

Camposol

/

+

, WKME

WalkMe

/

+

, DNUT

Krispy Kreme

/

+

, YOU

Clear Secure

/

+

, GS

Goldman Sachs

$378.13 /

+4.71 (+1.26%)

, MS

Morgan Stanley

$92.05 /

+0.38 (+0.41%)

, JPM

JPMorgan

$160.29 /

-0.11 (-0.07%)

, AMZN

Amazon.com

$3,346.75 /

-3.33 (-0.10%)

, F

Ford

$15.28 /

+0.17 (+1.13%)

, SAFO

Save Foods

/

+

, HOOD

Robinhood

/

+

Monday.com jumped in its…

ShowHide Related Items >><<
ZME Zhangmen Education
$13.43 /

-0.56 (-4.00%)

MS Morgan Stanley
$92.05 /

+0.38 (+0.41%)

JPM JPMorgan
$160.29 /

-0.11 (-0.07%)

HOOD Robinhood
/

+

GS Goldman Sachs
$378.13 /

+4.71 (+1.26%)

F Ford
$15.28 /

+0.17 (+1.13%)

DASH DoorDash
$154.18 /

+9.475 (+6.55%)

AMZN Amazon.com
$3,346.75 /

-3.33 (-0.10%)

ATY AcuityAds
$11.58 /

+1.01 (+9.56%)

MQ Marqeta
$31.50 /

+1.85 (+6.24%)

JANX Janux Therapeutics
$25.00 /

-9.17 (-26.84%)

TASK TaskUs
$31.34 /

+3.685 (+13.32%)

BZ Kanzhun
$37.67 /

+4.32 (+12.95%)

MNDY Monday.com
$194.99 /

+18.88 (+10.72%)

LFST LifeStance
$24.00 /

+2.27 (+10.45%)

ZETA Zeta Global
$8.26 /

-0.635 (-7.14%)

DIBS 1stDibs
$24.61 /

-3.53 (-12.54%)

DASH DoorDash
$154.18 /

+9.475 (+6.55%)

05/26/21 RBC Capital
DoorDash assumed with an Outperform at RBC Capital
05/20/21 DA Davidson
DoorDash price target lowered to $158 from $162 at DA Davidson
05/14/21
Fly Intel: Top five analyst upgrades
05/14/21 Wells Fargo
DoorDash upgraded to Overweight from Equal Weight at Wells Fargo
ZME Zhangmen Education
$13.43 /

-0.56 (-4.00%)

PCOR Procore
$83.98 /

-2.47 (-2.86%)

05/27/21 Berenberg
Berenberg started Procore at Buy on favorable construction environment
05/26/21 Berenberg
Procore initiated with a Buy at Berenberg
OTLY Oatly Group
$28.71 /

+2.01 (+7.53%)

DIDI DiDi
/

+

QNIU Qiniu
/

+

SVFD Save Foods
$8.80 /

+0.05 (+0.57%)

RGCB Regencell Bioscience
/

+

ELEV Elevation Oncology
/

+

CMSL Camposol
/

+

WKME WalkMe
/

+

DNUT Krispy Kreme
/

+

YOU Clear Secure
/

+

GS Goldman Sachs
$378.13 /

+4.71 (+1.26%)

06/09/21 Jefferies
Jefferies starts 'too cheap' Goldman Sachs at Buy
06/09/21 Jefferies
Goldman Sachs initiated with a Buy at Jefferies
06/01/21 Piper Sandler
Goldman Sachs price target raised to $420 from $385 at Piper Sandler
05/12/21 Wells Fargo
Summer travel should be catalyst for commercial aero, says Wells Fargo
MS Morgan Stanley
$92.05 /

+0.38 (+0.41%)

06/09/21 Jefferies
Jefferies starts 'compelling compounder' Morgan Stanley at Buy
06/09/21 Jefferies
Morgan Stanley initiated with a Buy at Jefferies
06/04/21 BofA
Morgan Stanley price target raised to $105 from $92 at BofA
06/01/21 Piper Sandler
Morgan Stanley price target raised to $93 from $87 at Piper Sandler
JPM JPMorgan
$160.29 /

-0.11 (-0.07%)

06/08/21 Wells Fargo
JPMorgan price target raised to $200 from $195 at Wells Fargo
05/06/21 JMP Securities
Walker & Dunlop price target raised to $130 from $70 at JMP Securities
04/30/21 Wells Fargo
JPMorgan price target raised to $195 from $190 at Wells Fargo
04/27/21 Atlantic Equities
JPMorgan downgraded to Neutral from Overweight at Atlantic Equities
AMZN Amazon.com
$3,346.75 /

-3.33 (-0.10%)

06/08/21 Piper Sandler
New Amazon offering targets Hims & Hers and others, says Piper Sandler
06/08/21 UBS
Snowflake price target raised to $300 from $275 at UBS
06/07/21 Loop Capital
Best Buy prices remain 'very competitive' to Amazon's, says Loop Capital
06/07/21 Roth Capital
iPower initiated with a Buy at Roth Capital
F Ford
$15.28 /

+0.17 (+1.13%)

06/04/21 JPMorgan
Ford price target raised to $18 from $16 at JPMorgan
05/28/21 Deutsche Bank
Deutsche starts Lordstown with Hold on 'considerable uncertainty'
05/27/21
Fly Intel: Top five analyst upgrades
05/27/21 Jefferies
Ford 'playing to its strengths' with new EV strategy, says Jefferies
SAFO Save Foods
/

+

HOOD Robinhood
/

+

MS Morgan Stanley
$92.05 /

+0.38 (+0.41%)

JPM JPMorgan
$160.29 /

-0.11 (-0.07%)

GS Goldman Sachs
$378.13 /

+4.71 (+1.26%)

F Ford
$15.28 /

+0.17 (+1.13%)

DASH DoorDash
$154.18 /

+9.475 (+6.55%)

AMZN Amazon.com
$3,346.75 /

-3.33 (-0.10%)

  • 16
    Jun
  • 11
    Jun
  • 11
    Jun
  • 08
    Jun
  • 10
    Jun
  • 11
    Jun
  • 10
    Jun
  • 09
    Jun
  • 10
    Jun
  • 10
    Jun
  • 20
    May
  • 14
    May
  • 20
    May
  • 20
    May
  • 09
    Dec
OTLY Oatly Group
$28.71 /

+2.01 (+7.53%)

MS Morgan Stanley
$92.05 /

+0.38 (+0.41%)

JPM JPMorgan
$160.29 /

-0.11 (-0.07%)

HOOD Robinhood
/

+

GS Goldman Sachs
$378.13 /

+4.71 (+1.26%)

F Ford
$15.28 /

+0.17 (+1.13%)

DASH DoorDash
$154.18 /

+9.475 (+6.55%)

AMZN Amazon.com
$3,346.75 /

-3.33 (-0.10%)

SAFO Save Foods
/

+

QNIU Qiniu
/

+

PCOR Procore
$83.98 /

-2.47 (-2.86%)

OTLY Oatly Group
$28.71 /

+2.01 (+7.53%)

JPM JPMorgan
$160.29 /

-0.11 (-0.07%)

HOOD Robinhood
/

+

GS Goldman Sachs
$378.13 /

+4.71 (+1.26%)

F Ford
$15.28 /

+0.17 (+1.13%)

DIDI DiDi
/

+

DASH DoorDash
$154.18 /

+9.475 (+6.55%)

AMZN Amazon.com
$3,346.75 /

-3.33 (-0.10%)

PCOR Procore
$83.98 /

-2.47 (-2.86%)

OTLY Oatly Group
$28.71 /

+2.01 (+7.53%)

MS Morgan Stanley
$92.05 /

+0.38 (+0.41%)

JPM JPMorgan
$160.29 /

-0.11 (-0.07%)

GS Goldman Sachs
$378.13 /

+4.71 (+1.26%)

F Ford
$15.28 /

+0.17 (+1.13%)

DASH DoorDash
$154.18 /

+9.475 (+6.55%)

AMZN Amazon.com
$3,346.75 /

-3.33 (-0.10%)

Conference/Events
European Hematology Association to hold virtual meeting » 04:55
06/12/21
06/12
04:55
06/12/21
04:55
APTO

Aptose Biosciences

$3.75 /

-1.79 (-32.31%)

, MBIO

Mustang Bio

$3.79 /

-0.03 (-0.79%)

, QURE

uniQure

$36.05 /

-0.63 (-1.72%)

, RIGL

Rigel Pharmaceuticals

$4.02 /

-0.16 (-3.83%)

, MGTA

Magenta Therapeutics

$11.57 /

-0.15 (-1.28%)

, MEIP

MEI Pharma

$3.28 /

+0.08 (+2.50%)

, CRIS

Curis

$8.00 /

-4.72 (-37.11%)

, XLRN

Acceleron

$133.36 /

+2.36 (+1.80%)

, EPZM

Epizyme

$8.53 /

+0.08 (+0.95%)

, INCY

Incyte

$82.59 /

-4.97 (-5.68%)

, ORTX

Orchard Therapeutics

$5.12 /

-0.05 (-0.97%)

, TGTX

TG Therapeutics

$37.81 /

-0.14 (-0.37%)

, EQ

Equillium

$6.12 /

-0.85 (-12.20%)

, JAZZ

Jazz Pharmaceuticals

$186.19 /

-0.21 (-0.11%)

, VRTX

Vertex Pharmaceuticals

$193.02 /

-23.93 (-11.03%)

, SGEN

Seagen

$156.27 /

-2.3 (-1.45%)

, IMRA

Imara

$8.56 /

-0.235 (-2.67%)

, GBT

Global Blood Therapeutics

$40.64 /

-1.01 (-2.42%)

, BGNE

BeiGene

$346.81 /

-6.09 (-1.73%)

, APLS

Apellis

$62.10 /

+1.33 (+2.19%)

, AGIO

Agios Pharmaceuticals

$57.80 /

-1.69 (-2.84%)

, FMTX

Forma Therapeutics

$22.81 /

-5.2 (-18.56%)

, KROS

Keros Therapeutics

$51.75 /

-0.61 (-1.17%)

, CYAD

Celyad

$5.75 /

-0.22 (-3.69%)

, ALXN

Alexion

$181.64 /

-0.41 (-0.23%)

EHA 2021 Virtual Congress…

EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$133.36 /

+2.36 (+1.80%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

QURE uniQure
$36.05 /

-0.63 (-1.72%)

ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

MEIP MEI Pharma
$3.28 /

+0.08 (+2.50%)

MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

KROS Keros Therapeutics
$51.75 /

-0.61 (-1.17%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

IMRA Imara
$8.56 /

-0.235 (-2.67%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

CYAD Celyad
$5.75 /

-0.22 (-3.69%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

BGNE BeiGene
$346.81 /

-6.09 (-1.73%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

AGIO Agios Pharmaceuticals
$57.80 /

-1.69 (-2.84%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
QURE uniQure
$36.05 /

-0.63 (-1.72%)

05/20/21 UBS
uniQure initiated with a Neutral at UBS
05/19/21 H.C. Wainwright
uniQure price target raised to $90 from $80 at H.C. Wainwright
04/26/21 Chardan
Chardan sees 'stock momentum' for uniQure after clinical hold lift
04/26/21 Credit Suisse
uniQure assumed with an Outperform at Credit Suisse
RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

06/11/21 BMO Capital
Rigel Pharmaceuticals coverage transferred at BMO Capital
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
04/13/21 Piper Sandler
Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
01/07/21
Fly Intel: Top five analyst initiations
MEIP MEI Pharma
$3.28 /

+0.08 (+2.50%)

04/26/21 Wells Fargo
MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
CRIS Curis
$8.00 /

-4.72 (-37.11%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
XLRN Acceleron
$133.36 /

+2.36 (+1.80%)

06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
05/19/21 Piper Sandler
Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
04/26/21 Credit Suisse
Acceleron assumed with an Outperform at Credit Suisse
03/23/21
Fly Intel: Top five analyst downgrades
EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
INCY Incyte
$82.59 /

-4.97 (-5.68%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
EQ Equillium
$6.12 /

-0.85 (-12.20%)

03/03/21
Fly Intel: Top five analyst initiations
03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

06/11/21 Roth Capital
Crispr Therapeutics reported 'robust' sickle cell data, says Roth Capital
06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 Stifel
Vertex shares look 'cheap' at aftermarket levels, says Stifel
06/11/21 Cantor Fitzgerald
Vertex Pharmaceuticals price target lowered to $281 from $285 at Cantor Fitzgerald
SGEN Seagen
$156.27 /

-2.3 (-1.45%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
IMRA Imara
$8.56 /

-0.235 (-2.67%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
BGNE BeiGene
$346.81 /

-6.09 (-1.73%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
APLS Apellis
$62.10 /

+1.33 (+2.19%)

05/20/21 UBS
Apellis initiated with a Buy at UBS
05/18/21 BMO Capital
Apellis price target raised to $68 from $64 at BMO Capital
05/17/21 Oppenheimer
Apellis price target raised to $67 from $64 at Oppenheimer
05/17/21 Raymond James
Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals
$57.80 /

-1.69 (-2.84%)

06/10/21 H.C. Wainwright
Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/30/21 Goldman Sachs
Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
04/30/21 Barclays
Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
03/30/21 Piper Sandler
Agios should rally on Forma Therapeutics data, says Piper Sandler
FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

03/31/21 H.C. Wainwright
Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
KROS Keros Therapeutics
$51.75 /

-0.61 (-1.17%)

12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
12/08/20 Piper Sandler
Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
11/18/20 Piper Sandler
Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
CYAD Celyad
$5.75 /

-0.22 (-3.69%)

03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
12/08/20 H.C. Wainwright
Celyad price target lowered to $18 from $22 at H.C. Wainwright
ALXN Alexion
$181.64 /

-0.41 (-0.23%)

05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
05/03/21 SVB Leerink
Alexion price target raised to $173 from $156 at SVB Leerink
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
XLRN Acceleron
$133.36 /

+2.36 (+1.80%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

QURE uniQure
$36.05 /

-0.63 (-1.72%)

ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

MEIP MEI Pharma
$3.28 /

+0.08 (+2.50%)

MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

KROS Keros Therapeutics
$51.75 /

-0.61 (-1.17%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

IMRA Imara
$8.56 /

-0.235 (-2.67%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

BGNE BeiGene
$346.81 /

-6.09 (-1.73%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

AGIO Agios Pharmaceuticals
$57.80 /

-1.69 (-2.84%)

  • 15
    Dec
  • 09
    Dec
  • 11
    Dec
  • 02
    Dec
  • 13
    Nov
  • 14
    Aug
  • 16
    Jul
  • 01
    Jul
  • 25
    Jun
  • 19
    Jun
VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

QURE uniQure
$36.05 /

-0.63 (-1.72%)

MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

IMRA Imara
$8.56 /

-0.235 (-2.67%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

Hot Stocks
Endo: Tennessee court issues orders regarding state court default judgment » 18:55
06/11/21
06/11
18:55
06/11/21
18:55
ENDP

Endo

$6.25 /

+0.2 (+3.31%)

Endo International…

Endo International announced that the Tennessee Court of Appeals recently issued several orders with respect to a default judgment order on liability entered by the Circuit Court for Sullivan County, Tennessee in April 2021 against its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals in Case No. C-41916, originally captioned as Staubus, et al. v. Purdue Pharma, L.P., et al. Specifically, on June 8, 2021, the Tennessee Court of Appeals declined to review the default judgment order on a discretionary basis on the ground that a contempt judgment becomes final upon the entry of punishment and is immediately appealable as of right. Today, the Tennessee Court of Appeals denied without prejudice the plaintiffs' motion to dismiss Endo's separate appeal as of right from the default judgment order and directed Endo to show cause as to why its appeal should not be dismissed on the procedural ground that portions of the default judgment order were not final. The Tennessee Court of Appeals also denied without prejudice Endo's motion to stay further proceedings in the trial court on the procedural ground that Endo must first seek a stay from the trial court. Matthew Maletta, Endo's Executive Vice President and Chief Legal Officer, commented: "As we previously stated, Endo believes the trial court's default judgment order was procedurally, factually and legally deficient. We therefore promptly appealed that order to the Tennessee Court of Appeals. The orders issued today by the Tennessee Court of Appeals do not dispose of Endo's appeal as of right. We will promptly take the actions directed by the Tennessee Court of Appeals and Endo will continue to seek a stay of further trial court proceedings including, if necessary, in the appellate courts." The company also intends to seek review by the Tennessee Supreme Court of the trial court's order permitting the substitution of new plaintiffs in the case after the Tennessee Court of Appeals denied Endo's application for discretionary review of that order on June 8, 2021.

ShowHide Related Items >><<
ENDP Endo
$6.25 /

+0.2 (+3.31%)

ENDP Endo
$6.25 /

+0.2 (+3.31%)

05/17/21 Citi
Endo price target raised to $11 from $10 at Citi
04/06/21 RBC Capital
Endo transferred with a Sector Perform at RBC Capital
03/08/21 Barclays
Endo price target raised to $7 from $6 at Barclays
03/04/21 Citi
Endo price target lowered to $10 from $11 at Citi
ENDP Endo
$6.25 /

+0.2 (+3.31%)

ENDP Endo
$6.25 /

+0.2 (+3.31%)

ENDP Endo
$6.25 /

+0.2 (+3.31%)

ENDP Endo
$6.25 /

+0.2 (+3.31%)

Hot Stocks
Ascendis Pharma announces extension of FDA review period for lonapegsomatropin » 18:01
06/11/21
06/11
18:01
06/11/21
18:01
ASND

Ascendis Pharma

$130.26 /

+1.7 (+1.32%)

Ascendis Pharma A/S…

Ascendis Pharma A/S announced that the FDA notified the company that information the company submitted in connection with the FDA's ongoing review of the Biologics License Application, or BLA, for lonapegsomatropin for the treatment of pediatric growth hormone deficiency constituted a major amendment to the BLA. Accordingly, the FDA has extended the Prescription Drug User Fee Act goal date by three months, to September 25, 2021.

ShowHide Related Items >><<
ASND Ascendis Pharma
$130.26 /

+1.7 (+1.32%)

ASND Ascendis Pharma
$130.26 /

+1.7 (+1.32%)

06/01/21 Canaccord
Ascendis Pharma price target raised to $196 from $190 at Canaccord
05/26/21 JPMorgan
Ascendis should be bought into second half catalysts, says JPMorgan
05/11/21 JPMorgan
Ascendis shares offer 'very compelling entry point,' says JPMorgan
04/13/21 Canaccord
Ascendis Pharma oncology platform remains underappreciated, says Canaccord
ASND Ascendis Pharma
$130.26 /

+1.7 (+1.32%)

  • 08
    Jul
Recommendations
Scholar Rock coverage transferred at BMO Capital » 17:38
06/11/21
06/11
17:38
06/11/21
17:38
SRRK

Scholar Rock

$31.76 /

+1.95 (+6.54%)

BMO Capital transferred…

BMO Capital transferred coverage of Scholar Rock to analysts Gary Nachman and Matthew Luchini, who maintained an Outperform rating and $76 price target on the stock.

ShowHide Related Items >><<
SRRK Scholar Rock
$31.76 /

+1.95 (+6.54%)

SRRK Scholar Rock
$31.76 /

+1.95 (+6.54%)

04/26/21 Credit Suisse
Scholar Rock assumed with an Outperform at Credit Suisse
04/06/21 JPMorgan
Scholar Rock weakness overdone after TOPAZ results, says JPMorgan
01/25/21 BMO Capital
Scholar Rock price target raised to $79 from $54 at BMO Capital
01/21/21 Wedbush
Scholar Rock price target raised to $66 from $47 at Wedbush
SRRK Scholar Rock
$31.76 /

+1.95 (+6.54%)

  • 29
    Oct
SRRK Scholar Rock
$31.76 /

+1.95 (+6.54%)

Recommendations
Morphic coverage transferred at BMO Capital » 17:37
06/11/21
06/11
17:37
06/11/21
17:37
MORF

Morphic

$62.93 /

+2.67 (+4.43%)

BMO Capital transferred…

BMO Capital transferred coverage of Morphic to analysts Gary Nachman and Matthew Luchini, who maintained an Outperform rating and $102 price target on the stock.

ShowHide Related Items >><<
MORF Morphic
$62.93 /

+2.67 (+4.43%)

MORF Morphic
$62.93 /

+2.67 (+4.43%)

03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
03/01/21 Wells Fargo
Morphic Holding price target raised to $103 from $40 at Wells Fargo
02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
MORF Morphic
$62.93 /

+2.67 (+4.43%)

  • 03
    Mar
MORF Morphic
$62.93 /

+2.67 (+4.43%)

Recommendations
TCR2 Therapeutics coverage transferred at BMO Capital » 17:36
06/11/21
06/11
17:36
06/11/21
17:36
TCRR

TCR2 Therapeutics

$17.49 /

-0.33 (-1.85%)

BMO Capital transferred…

BMO Capital transferred coverage of TCR2 Therapeutics to analyst Matthew Luchini, who maintained an Outperform rating and $53 price target on the stock.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$17.49 /

-0.33 (-1.85%)

TCRR TCR2 Therapeutics
$17.49 /

-0.33 (-1.85%)

05/14/21 Wedbush
TCR2 Therapeutics price target lowered to $45 from $57 at Wedbush
03/12/21 Mizuho
TCR2 Therapeutics price target lowered to $51 from $58 at Mizuho
03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
TCRR TCR2 Therapeutics
$17.49 /

-0.33 (-1.85%)

  • 20
    Jan
  • 29
    Jul
Recommendations
Schrodinger coverage transferred at BMO Capital » 17:35
06/11/21
06/11
17:35
06/11/21
17:35
SDGR

Schrodinger

$77.43 /

+1.05 (+1.37%)

BMO Capital transferred…

BMO Capital transferred coverage of Schrodinger to analyst Gary Nachman, who maintained an Outperform rating and $104 price target on the stock.

ShowHide Related Items >><<
SDGR Schrodinger
$77.43 /

+1.05 (+1.37%)

SDGR Schrodinger
$77.43 /

+1.05 (+1.37%)

05/25/21 Craig-Hallum
Schrodinger initiated with a Buy at Craig-Hallum
03/24/21 BMO Capital
Schrodinger price target lowered to $104 from $110 at BMO Capital
03/15/21 Jefferies
Schrodinger shares should recover on beats, discovery progress, says Jefferies
01/25/21 BMO Capital
Schrodinger price target raised to $117 from $97 at BMO Capital
SDGR Schrodinger
$77.43 /

+1.05 (+1.37%)

  • 13
    Aug
SDGR Schrodinger
$77.43 /

+1.05 (+1.37%)

Recommendations
Replimune Group coverage transferred at BMO Capital » 17:35
06/11/21
06/11
17:35
06/11/21
17:35
REPL

Replimune Group

$34.02 /

+0.99 (+3.00%)

BMO Capital transferred…

BMO Capital transferred coverage of Replimune Group to analyst Matthew Luchini, who maintained an Outperform rating and $57 price target on the stock.

ShowHide Related Items >><<
REPL Replimune Group
$34.02 /

+0.99 (+3.00%)

REPL Replimune Group
$34.02 /

+0.99 (+3.00%)

04/19/21 Piper Sandler
Oncorus selloff has nothing to do with fundamentals, says Piper Sandler
02/05/21 H.C. Wainwright
Replimune Group price target raised to $60 from $58 at H.C. Wainwright
12/16/20 Wedbush
Replimune Group, Harpoon Therapeutics removed from Best Ideas List at Wedbush
11/17/20 BTIG
Replimune Group initiated with a Buy at BTIG
REPL Replimune Group
$34.02 /

+0.99 (+3.00%)

  • 22
    Oct
Recommendations
Rigel Pharmaceuticals coverage transferred at BMO Capital » 17:34
06/11/21
06/11
17:34
06/11/21
17:34
RIGL

Rigel Pharmaceuticals

$4.02 /

-0.16 (-3.83%)

BMO Capital transferred…

BMO Capital transferred coverage of Rigel Pharmaceuticals to analyst Gary Nachman, who maintained an Outperform rating and $9 price target on the stock.

ShowHide Related Items >><<
RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
04/13/21 Piper Sandler
Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

Recommendations
Nuvation Bio coverage transferred at BMO Capital » 17:34
06/11/21
06/11
17:34
06/11/21
17:34
NUVB

Nuvation Bio

$11.65 /

-1.54 (-11.68%)

BMO Capital transferred…

BMO Capital transferred coverage of Nuvation Bio to analyst Matthew Luchini, who maintained an Outperform rating and $17 price target on the stock.

ShowHide Related Items >><<
NUVB Nuvation Bio
$11.65 /

-1.54 (-11.68%)

NUVB Nuvation Bio
$11.65 /

-1.54 (-11.68%)

04/06/21
Fly Intel: Top five analyst initiations
04/06/21 RBC Capital
Nuvation Bio initiated with an Outperform at RBC Capital
03/08/21 Jefferies
Nuvation Bio initiated with a Buy at Jefferies
03/08/21 Cowen
Nuvation Bio initiated with an Outperform at Cowen
NUVB Nuvation Bio
$11.65 /

-1.54 (-11.68%)

NUVB Nuvation Bio
$11.65 /

-1.54 (-11.68%)

Recommendations
Ionis Pharmaceuticals coverage transferred at BMO Capital » 17:33
06/11/21
06/11
17:33
06/11/21
17:33
IONS

Ionis Pharmaceuticals

$37.93 /

-0.285 (-0.75%)

BMO Capital transferred…

BMO Capital transferred coverage of Ionis Pharmaceuticals to analyst Gary Nachman, who maintained an Outperform rating and $70 price target on the stock.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$37.93 /

-0.285 (-0.75%)

IONS Ionis Pharmaceuticals
$37.93 /

-0.285 (-0.75%)

06/10/21 Benchmark
Biogen's Aduhelm approval has 'nothing to do' with Ionis, says Benchmark
05/07/21 UBS
Ionis Pharmaceuticals upgraded to Neutral from Sell at UBS
03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
IONS Ionis Pharmaceuticals
$37.93 /

-0.285 (-0.75%)

IONS Ionis Pharmaceuticals
$37.93 /

-0.285 (-0.75%)

IONS Ionis Pharmaceuticals
$37.93 /

-0.285 (-0.75%)

Recommendations
Halozyme coverage transferred at BMO Capital » 17:32
06/11/21
06/11
17:32
06/11/21
17:32
HALO

Halozyme

$42.82 /

+1.09 (+2.61%)

BMO Capital transferred…

BMO Capital transferred coverage of Halozyme to analyst Matthew Luchini, who maintained an Outperform rating and $64 price target on the stock.

ShowHide Related Items >><<
HALO Halozyme
$42.82 /

+1.09 (+2.61%)

HALO Halozyme
$42.82 /

+1.09 (+2.61%)

05/17/21 SVB Leerink
Halozyme initiated with an Outperform at SVB Leerink
05/17/21 SVB Leerink
Halozyme initiated with an Outperform at SVB Leerink
05/11/21 Piper Sandler
Halozyme downgraded to Neutral from Overweight at Piper Sandler
01/25/21 BMO Capital
Halozyme price target raised to $65 from $56 at BMO Capital
HALO Halozyme
$42.82 /

+1.09 (+2.61%)

HALO Halozyme
$42.82 /

+1.09 (+2.61%)

Recommendations
Exicure coverage transferred at BMO Capital » 17:32
06/11/21
06/11
17:32
06/11/21
17:32
XCUR

Exicure

$1.68 /

-0.06 (-3.45%)

BMO Capital transferred…

BMO Capital transferred coverage of Exicure to analyst Gary Nachman, who maintained an Outperform rating and $6 price target on the stock.

ShowHide Related Items >><<
XCUR Exicure
$1.68 /

-0.06 (-3.45%)

XCUR Exicure
$1.68 /

-0.06 (-3.45%)

12/18/20 BMO Capital
Exicure initiated with an Outperform at BMO Capital
XCUR Exicure
$1.68 /

-0.06 (-3.45%)

XCUR Exicure
$1.68 /

-0.06 (-3.45%)

Recommendations
Fate Therapeutics coverage transferred at BMO Capital » 17:31
06/11/21
06/11
17:31
06/11/21
17:31
FATE

Fate Therapeutics

$89.77 /

+1.28 (+1.45%)

BMO Capital transferred…

BMO Capital transferred coverage of Fate Therapeutics to analyst Matthew Luchini, who maintained a Market Perform rating and $80 price target.

ShowHide Related Items >><<
FATE Fate Therapeutics
$89.77 /

+1.28 (+1.45%)

FATE Fate Therapeutics
$89.77 /

+1.28 (+1.45%)

06/07/21 H.C. Wainwright
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
06/04/21 Roth Capital
Fate Therapeutics duration response remains unknown, says Roth Capital
06/04/21 Piper Sandler
Fate's Phase I data showed 8 patients achieved ORR, says Piper Sandler
04/26/21 Jefferies
Fate Therapeutics assumed with a Buy at Jefferies
FATE Fate Therapeutics
$89.77 /

+1.28 (+1.45%)

  • 06
    Jan
FATE Fate Therapeutics
$89.77 /

+1.28 (+1.45%)

Recommendations
Alnylam coverage transferred at BMO Capital » 17:31
06/11/21
06/11
17:31
06/11/21
17:31
ALNY

Alnylam

$165.16 /

+1.96 (+1.20%)

BMO Capital transferred…

BMO Capital transferred coverage of Alnylam to analyst Gary Nachman, who maintained a Market Perform rating and $174 price target on the stock.

ShowHide Related Items >><<
ALNY Alnylam
$165.16 /

+1.96 (+1.20%)

ALNY Alnylam
$165.16 /

+1.96 (+1.20%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
ALNY Alnylam
$165.16 /

+1.96 (+1.20%)

Recommendations
AbCellera coverage transferred at BMO Capital » 17:29
06/11/21
06/11
17:29
06/11/21
17:29
ABCL

AbCellera

$25.89 /

+1.01 (+4.06%)

BMO Capital transferred…

BMO Capital transferred coverage of AbCellera to analyst Gary Nachman, who maintained an Outperform rating and $52 price target on the stock.

ShowHide Related Items >><<
ABCL AbCellera
$25.89 /

+1.01 (+4.06%)

ABCL AbCellera
$25.89 /

+1.01 (+4.06%)

03/30/21 SVB Leerink
AbCellera price target lowered to $45 from $52 at SVB Leerink
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
01/26/21 Berenberg
Eli Lilly data 'incrementally positive' for AbCellera, says Berenberg
ABCL AbCellera
$25.89 /

+1.01 (+4.06%)

  • 11
    Dec
ABCL AbCellera
$25.89 /

+1.01 (+4.06%)

ABCL AbCellera
$25.89 /

+1.01 (+4.06%)

Syndicate
Broadcom files automatic mixed securities shelf  17:26
06/11/21
06/11
17:26
06/11/21
17:26
AVGO

Broadcom

$470.68 /

+1.95 (+0.42%)

 
ShowHide Related Items >><<
AVGO Broadcom
$470.68 /

+1.95 (+0.42%)

AVGO Broadcom
$470.68 /

+1.95 (+0.42%)

06/07/21 Baird
Broadcom price target raised to $550 from $500 at Baird
06/07/21 Baird
Broadcom price target raised to $550 from $500 at Baird
06/04/21 Morgan Stanley
Broadcom price target raised to $555 from $538 at Morgan Stanley
06/04/21 Wells Fargo
Broadcom price target raised to $475 from $450 at Wells Fargo
AVGO Broadcom
$470.68 /

+1.95 (+0.42%)

AVGO Broadcom
$470.68 /

+1.95 (+0.42%)

AVGO Broadcom
$470.68 /

+1.95 (+0.42%)

AVGO Broadcom
$470.68 /

+1.95 (+0.42%)

Syndicate
Sigma Labs files $50M mixed securities shelf  17:25
06/11/21
06/11
17:25
06/11/21
17:25
SGLB

Sigma Labs

$4.25 /

-0.155 (-3.52%)

 
ShowHide Related Items >><<
SGLB Sigma Labs
$4.25 /

-0.155 (-3.52%)

SGLB Sigma Labs
$4.25 /

-0.155 (-3.52%)

05/20/21 H.C. Wainwright
Sigma Labs initiated with a Buy at H.C. Wainwright
SGLB Sigma Labs
$4.25 /

-0.155 (-3.52%)

  • 08
    Jan
SGLB Sigma Labs
$4.25 /

-0.155 (-3.52%)

Syndicate
Heat Biologics files to sell 403,025 shares of common stock  17:20
06/11/21
06/11
17:20
06/11/21
17:20
HTBX

Heat Biologics

$7.60 /

-1.93 (-20.25%)

 
ShowHide Related Items >><<
HTBX Heat Biologics
$7.60 /

-1.93 (-20.25%)

HTBX Heat Biologics
$7.60 /

-1.93 (-20.25%)

05/06/21 Alliance Global Partners
Heat Biologics price target lowered to $32 from $40 at Alliance Global Partners
03/02/21 Cantor Fitzgerald
Heat Biologics initiated with an Overweight at Cantor Fitzgerald
02/09/21 Alliance Global Partners
Heat Biologics price target raised to $40 from $5 at Alliance Global Partners
02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
HTBX Heat Biologics
$7.60 /

-1.93 (-20.25%)

HTBX Heat Biologics
$7.60 /

-1.93 (-20.25%)

HTBX Heat Biologics
$7.60 /

-1.93 (-20.25%)

Conference/Events
Cantor biotech/biopharma analysts hold an analyst/industry conference call » 17:16
06/11/21
06/11
17:16
06/11/21
17:16

Biotech Analyst Young and…

Biotech Analyst Young and Biopharma Analyst Chen, along with Key Opinion Leader Dr.Akil Merchant, Associate Professor of Medicine at Cedars-Sinai Health System, discuss novel treatments for Acute Myeloid Leukemia (AML) and other hematological malignancies presented at the recently-held EHA Virtual Meeting, on an Analyst/Industry conference call to be held on June 14 at 11 am.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.